-
Yang Sen is burning $1 billion for this product. Why?
Time of Update: 2017-06-06
On May 26, YANGSEN company and protago NIST therapeutics company reached a global exclusive license and cooperation agreement on the development, production and commercialization of ptg-200, the first
-
Biological similar medicine ushers in a new era! Who is the first to win in the research and development of six monoclonal antibody analogues in China?
Time of Update: 2017-06-05
In 2016, among the top 10 drugs in the world, there are 7 biological drugs, 6 of which are monoclonal antibodies Xiumeile, the king of monoclonal antibodies, has a sales volume of US $16 billion, whil
-
Talk about tenofovir again! Pay homage to the medical practitioners who witnessed the changes of the industry
Time of Update: 2017-06-05
With the approval of Chengdu Beite, guangshengtang and Qilu pharmaceutical tenofovir one after another, the controversy of tenofovir's first model has finally come to an end Shopping malls are like ba
-
12 generic drugs are included in the priority review! But the generic drug declaration dropped by 60%, why?
Time of Update: 2017-06-02
On the one hand, 12 generic drugs have been included in the priority review list On the other hand, the generic drug application has declined precipitously Compared with 2015, the generic drug applica
-
Hope to say goodbye to the downturn! Paediatric generic drugs will become a new hotspot
Time of Update: 2017-06-02
Recently, CFDA released the official draft of "technical guidelines for extrapolation of adult drug use data to pediatric population", which is undoubtedly a great benefit to pediatric drug research a
-
The consistency evaluation must be speeded up when the pharmaceutical export enterprises seize the domestic market
Time of Update: 2017-06-02
On June 1, CDE publicized the list of the 18th batch of varieties to be included in the priority review 12 acceptance numbers from four enterprises, including Xiansheng Dongyuan, Zhengda Tianqing, Shi
-
Big market ignored! Understand the gold digging opportunities of enterprises in the heavy drug area of urinary system
Time of Update: 2017-05-31
According to Chinese urological disease diagnosis and treatment guidelines 2014 edition, urological diseases are divided into: tumors mainly include: renal cell carcinoma, bladder cancer, prostate ca
-
The return of the king of generic drugs in China
Time of Update: 2017-05-29
On May 18, duloxetine hydrochloride enteric coated capsules (20mg, 30mg, 60mg) of Prinston, a US subsidiary of Huahai pharmaceutical, were approved by FDA According to Huahai pharmaceutical's annual r
-
Look at each other coldly! Thinking about a list of children's drugs
Time of Update: 2017-05-27
One year later, the national health and Family Planning Commission, together with other relevant departments, released the second list of children's drugs to encourage R & D Application on May 12 Ther
-
Generics are already sharpening their knives. How will the cakes in the market be distributed?
Time of Update: 2017-05-27
Another batch of priority review lists have been released The priority review does reduce the waiting time for approval, which is potentially behind the more intense time to market Originally, the pac
-
Hengrui R & D is short of money and people?! On the difficulty of China's innovative drugs to pass the border from the perspective of "one brother of R & D"
Time of Update: 2017-05-25
With the continuous reform of the review and approval system of innovative drugs, especially the recent three drafts issued by CFDA, the opening of clinical trial base and 60 day period of clinical ap
-
Rapid growth of expectorant Market: over 12 billion yuan in scale, 90% of the top ten varieties
Time of Update: 2017-05-24
With the development of the aging society, the market of antitussive and expectorant drugs is increasing According to the data of MI Nei net HDM system, in 2016, the market scale of respiratory system
-
Top 15 generic companies are out! The company has 330 andas and 1500 products are on the market every year
Time of Update: 2017-05-23
In 2016, the top 15 generic pharmaceutical companies were ranked! The top three have total sales of nearly $30 billion Generic drugs are facing global opportunities, especially bio generic drugs At th
-
The third pharmaceutical enterprise with a market value of 100 billion was born! Why are they? Who's next?
Time of Update: 2017-05-22
Men are afraid of entering the wrong line, women are afraid of marrying the wrong man From the perspective of business, the reason why Shanghai Laishi is recognized by the capital market is that it has made great contributions to its business Its main business of blood products is a highly regulated scarce resource field The scarcity lies in that: the first batch of blood products will not be produced in China since 2001
-
There is a long way to go in the research and development of innovative drugs in China. Why are these innovative drug companies becoming the model of new drug research and development in China?
Time of Update: 2017-05-22
Many years ago, the intuitive impression of China's pharmaceutical industry to the world was "cheap API supplier" and "low-end generic manufacturer" The so-called title of the world's largest producer
-
International pharmaceutical companies lose their luster? Opportunity for local pharmaceutical companies?
Time of Update: 2017-05-21
No matter what the face is, multinational pharmaceutical companies in China are starting to decline, which directly causes most of their performance growth in recent years to slow down from more than
-
Wang Jin: R & D outsourcing and restructuring is a feast for investors?
Time of Update: 2017-05-18
R & D outsourcing, improving efficiency and reducing cost, has always been the eternal theme of biomedical industry and innovative R & D it constantly promotes the vigorous development of cro service
-
Will the priority approval of generic drugs make the market tremble?
Time of Update: 2017-05-18
Since 2016, CFDA has started the priority review and approval Now, more than one year after the priority review, the first batch of priority review drugs have already been approved Half of 2017 is abo
-
The 6.6 billion unsold pharmaceutical company now has a market value of over 20 billion yuan. What happened?
Time of Update: 2017-05-15
Relying on a product, a le, Jialin, with the "wolf" team led by Liu Wei, has been cutting through all the difficulties, with the market growth rate of more than 50% for 10 consecutive years Next, Liu
-
Guo Ming, Yasheng pharmaceutical: China's pharmaceutical innovation ushers in a golden age of favorable time, favorable place and harmonious people!
Time of Update: 2017-05-14
On May 12, 2017, the summit of future leaders of China's pharmaceutical industry was held in Beijing At the meeting, Guo Ming, general manager of Yasheng pharmaceutical, expressed his views on the for
